期刊文献+

p53、PTEN和VEGF在胃癌组织中的表达及意义 被引量:6

Expression and significance of p53,PTEN,VEGF in gastric cancer tissue
暂未订购
导出
摘要 目的探讨p53、PTEN、VEGF表达在胃癌发生、发展中的作用及其相关影响因素。方法采用免疫组织化学法检测80份胃癌组织中p53、PTEN、VEGF表达,并分析其与胃癌临床病理特征的关系。结果 p53、PTEN、VEGF在胃癌组织中的阳性表达率依次为55%(44/80)、92.5%(74/80)、52.5%(42/80);胃癌组织中p53、VEGF表达阳性率明显高于对照组,P<0.01。三者表达与性别、年龄、肿瘤分化程度、浸润情况、淋巴结转移等均无明显相关性;任意两个指标之间相关性亦不显著。结论 p53、VEGF对胃癌的诊断有一定价值;p53、VEGF、PTEN对胃癌肿瘤分化、浸润和转移等的诊断价值不大,各指标间的相关性不显著。 Objective To investigate the roles of p53,phosphatase and tensin homolog deleted on chromosometen(PTEN) and vascular endothelial growth factor(VEGF) expression in the occurrence and development of gastric cancer,and to analyse their related factors.Methods The expression of p53,PTEN and VEGF protein were detected by immunohistochemical method in 80 patients with gastric carcer,and their corresponding clinical data were analysed retrospectively.Results The positive expression rates of p53,PTEN and VEGF protein in gastric cancer tissue were 44/ 80(55%),74/80(92.5%),42/80(52.5%).The positive expression rates of p53,VEGF were higher than those in healthy controls(P0.05).The positive expression rates of p53,PTEN and VEGF protein were not closely relevant to the gender,age,differentiation,invasion and metastasis;no significant correlations were found between any two indexes.Conclusion p53 and VEGF play important roles in gastric cancer diagnosis,but p53,VEGF and PTEN play small roles in cancer differentiation,invasion and metastasis,and there are no closely correlations among the three indexes.
出处 《山东医药》 CAS 2012年第7期18-20,共3页 Shandong Medical Journal
基金 江苏省自然科学基金资助项目(BK2008232)
关键词 P53 人第10号染色体缺失的磷酸酶及张力蛋白同源基因 血管内皮生长因子 胃肿瘤 胃癌 p53 phosphatase and tensin homolog deleted on chromosometen vascular endothelial growth factor gastric cancer
  • 相关文献

参考文献5

二级参考文献50

  • 1肖炜明,施瑞华,丁岩冰,龚卫娟,丁永玲,薛艳.胃癌组织中EGFR和COX-2表达的意义及其相关性[J].世界华人消化杂志,2007,15(2):123-128. 被引量:14
  • 2Goberdhan DC,Wilson C.PTEN:tumour suppressor,multifunctional growth regulator and more[J].Hum Mol Genet,2003,12(2):R239-248.
  • 3Chada S,Mhashilkar A,Roth JA,et al.Development of vaccines against self-antigens:the p53 paradigm[J].Curr Opin Drug Discov Devel,2003,6(2):169-173.
  • 4Trigiante G,Lu X.ASPP[corrected] and cancer[J].Nat Rev Cancer,2006,6(3):217-226.
  • 5Risinger JI,Hayes AK,Berchuck A,et al.PTEN/MMACl mutations in endometrial cancers[J].Cancer Res,1997,57 (21):4736-4738.
  • 6Li DM,Sun H.TEPI,encoded by a candidate tumor suppressor locus,is a novel protein tyresine phosphatase regulated by transforming growth factor beta[J].Cancer Res,1997,57(11):2124-2129.
  • 7Su JD,Mayo LD,Donner DB,et al.PTEN and phosphatidylinositol 3'-kinase inhibiturs up-regulate p53 and block tumor-induced angiogenesis:evidence for an effect on the tumor and endothelial compartment[J].Cancer Res,2003,63(13):3585-3592.
  • 8Rami-Porta R, Crowley J J, Goldstraw P. The revised TNM staging system for lung cancer [J] Ann Thorac Cardiovasc Surg, 2009,15 ( 1 ) : 4-- 9.
  • 9Steck PA, Pershouse MA, Tasser SA, et al.Identification of a candidate tumor suppressor gene MMAC at chromosome q23. 3 that is mutated in muhiple advanced cancels[J]. Nat Genet, 1997, 15 (4) : 356--362.
  • 10Sun H,Lesche R,Li DM,et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3, 4, 5,-trisphosphate and Akt/ protein kinase B signaling pathway [J]. Proc Natt Aead Sci USA,1999,96(11):6199--6204.

共引文献46

同被引文献41

  • 1邓昊,吴人亮,陈莹,周红艳,黄萱,刘丽江.应用组织芯片技术检测胃癌组织中PTEN、Survivin和p21ras蛋白的表达[J].华中科技大学学报(医学版),2006,35(3):284-287. 被引量:3
  • 2Kim C, Mulder K, Spratlin J. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer[J]. Oncologist, 2014,19 (10) : 1046-1049.
  • 3Lu X, Liu DP, Xu Y. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis [J]. Oncogene, 2013,32 (23) : 2900-2906.
  • 4Yamashita K, Waraya M, Katoh H, et al. Epigenetic conversion on p53 pathway in human cancer: the clinical potential of p53 mutation status as a predictive biomarker for drug sensitivity by epigenetic treatment[J]. Cancer Res, 2013, 73(8 Supplement) : 4662-4671.
  • 5Yang Z, Yuan XG, Chen J, et al. Reduced expression of PTEN and increased PTEN phosphorylation at residue Ser380 in gastric cancer tissues: a novel mechanism of PTEN inactivation[J]. Clin Res Hepatol Gastroenterol, 2013,37 (1) : 72-79.
  • 6Busuttil RA, Zapparoli GV, Haupt S, et al. Role of p53 in the progression of gastric cancer[J]. Oneotarget, 2014,5 (23): 12016-12025.
  • 7Saeki N, Ono H, Sakamoto H, et al. Genetic factors related to gastric cancer susceptibility identified using a genome-wide association study[J]. Cancer Sci,2013,104(1) :1-8.
  • 8Kluth M, Harasimowicz S, Burkhardt L, et al. Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer[J]. Int J Cancer, 2014, 135 (6):1369-1380.
  • 9Leslie NR, den Hertog J. Mutant PTEN in cancer: worse than nothing[J]. Cell,2014,157(3) : 527-529.
  • 10Dean SJ, Perks CM, Holly JM, et al. Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer[J]. Am J Clin Pathol,2014,141(3) :323-333.

引证文献6

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部